The same conclusion was reached by the meta-analysis by Cao et al. who found that the risk of pancreatic cancer with GLP-1 RA treatment was similar to that observed in the placebo arm of randomized controlled trials [76]. This evidence concerns the gene GLP1R and familial pancreatic carcinoma.